Antiplatelet Drug Resistances and Ischemic Events

The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.

Main objective:

• to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of ischemic events during the 3-year follow-up.

Secondary objectives:

• primary outcome in each pre-specified sub-group : patients with coronary artery disease, ischemic stroke or peripheral arterial disease as main qualifying disease at entry,
• to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of bleeding events during the 3-year follow-up,
• to investigate potential determinants of platelet reactivity at entry in the study

Inclusion criteria

• Documented symptomatic ischemic atherothrombotic disease treated by aspirin, clopidogrel or both.

Exclusion criteria

• Known platelet disorder
• Chronic treatment by antiplatelet drugs other than aspirin or clopidogrel.
• Chronic anticoagulant treatment
• Chronic non steroid anti inflammatory drug treatment
• Active cancer
• Ongoing aspirin or clopidogrel treatment taken for more than 5 years prior to inclusion